Selenium Group Research Articles

6662 Effect of Selenium Supplementation on Mild Graves’ Ophthalmopathy at a Tertiary Hospital - A Six-Month Open-Labelled, Assessor-Masked, Randomized-Controlled Trial

Abstract Disclosure: J.M. Flores: None. N.G. Sioson: None. J.D. Uy-Ho: None. A.L. Suller-Pansacola: None. Graves’ orbitopathy is associated with increased oxidative stress. Selenium, with its antioxidant and immunoregulatory actions, has been proposed as an adjuvant therapy. Objective: This study was undertaken to determine whether selenium supplementation for six months can decrease signs and prevent worsening of mild Graves ophthalmopathy among Filipinos. Methods: We conducted an open-labelled, assessor-masked, Randomized-Controlled Trial on patients with mild Graves’ ophthalmopathy wherein one arm was assigned to standard of care (eye drops) only for a period of six months while another arm was assigned to 200 ug/day oral Selenium supplementation alongside standard of care. Population: Adult patients with Graves’ hyperthyroidism, with at least one sign of mild ophthalmopathy with GO disease duration of less than 18 months Results: Independent Sample T-test, Mann-Whitney U test and Fisher’s Exact/Chi-square test were used to determine the difference of mean, rank and frequency, between patients given Selenium versus patients given standard of care. Paired Sample T-test, Wilcoxon Sign rank test and McNemar test were used to determine the difference of mean, rank and frequency on patients from initial to 3rd month or 6th month observation. Null hypotheses were rejected at 0.05α-level of significance. There was a significant difference in Clinical Activity Score (CAS) between patients given selenium supplementation and those assigned to standard of care. On initial examination for the Selenium group, 14 eyes (33.33%) had a CAS score of 0, which increased to 27 eyes (64.29%) on the third month and ended to a 26 eyes (61.9%) at the sixth month of treatment. For the non-selenium group, 11 eyes had a CAS score of zero initially, increased to 16 eyes (and 38.1%) then finally arrived to a total count of 14 eyes (33.33%). Improvement in CAS may be attributed specifically to improvement in caruncle/plical swelling showing a significant difference (p-value 0.040). Comparing the two groups, a statistical significance in CAS is noted between the treatment versus the control group with a p-value of 0.017 on the 6th month. Conclusion: Selenium supplementation provided significant benefit in terms of decreasing signs and preventing worsening of mild GO through improved CAS score. Further studies exploring the baseline and end of treatment selenium concentrations in the Philippines may be warranted. Presentation: 6/3/2024

Nutritional Impacts of Dietary Selenium, Iodine and their Interaction on Egg Performance, and Antioxidant Profile in Laying Longyuan Duck Breeders.

The present study aimed to optimize the combined effect of dietary selenium (SE) and iodine (ID) on the productive and reproductive performance and antioxidant capacity of Longyuan breeding ducks. A total of 288 Longyan duck breeders aged 20 wk were randomly assigned to four groups with six replicates (n = 72 ducks/group; 12 ducks/replicate). A 2 × 2 factorial arrangement experiment was performed and included 2 supplementation levels of each SE and ID for 200 days of the experimental period. The first group (SE0/ID0) received a basal diet without SE or ID supplementation and was considered to be the control group, whereas the other three groups, SE0/ID4, SE2/ID0 and SE2/ID4, received a basal diet supplemented with 0.4 mg ID/kg, 0.2 mg SE/kg or 0.2 mg SE supplemented with 0.4 mg ID/kg, respectively. The results indicated that the albumin height of the SE2/ID0 group was lower (P < 0.05) than that of the control group, that the egg shape index of the SE2/ID4 and SE0/ID4 groups were lower (P < 0.05) than that of the control group (SE0/ID0), and that the SE concentration significantly increased (P < 0.05) in the SE2/ID0 and SE2/ID4 groups. Hatchability and embryonic mortality improved (P < 0.05) in the SE2/ID0 group. Plasma GSH-Px activity was increased (P < 0.05) by reducing the concentration of malondialdehyde (MDA) in the SE groups. In addition, the tibia length significantly increased (P < 0.05) in the ID (SE0/ID4 and SE2/ID4) groups compared with that in the control group, the plasma content of IGF-1 in the SE2/ID4 and SE0/ID4 groups were greater (P < 0.05) than that in the control group, and the bone mineral content increased (P > 0.05) in the SE2/ID0 and SE0/ID0 groups. Compared with those in the other groups, the mRNA expression of antioxidant-related genes, including Nrf2 and SHMT1 in the SE2/ID4 group was upregulated (P > 0.05), especially in the SE2/ID4 group. Overall, dietary treatment with SE2/ID4 (0.2 mg SE in 0.4 mg ID/kg diet) could be a suitable feed supplement for improving the the egg quality, health status, endogenous antioxidant content, antioxidant-related gene expression and pre-hatching quality of Longyuan duck breeders.

Effects of in ovo supplementation of selenium (Se) and zinc (zn) on hatchability and production performance of broiler chickens.

The current research was conducted to assess the effect of in ovo feeding (IOF) of selenium (Se) and zinc (Zn) on hatchability, production performance, liver, intestinal morphology, antioxidant levels and expression levels of immune-related genes in broiler chickens. A total of 400 fertilized eggs were equally divided into four groups: control (non-injected), sham (in ovo injection of 0.75% NaCl), Se (@ 1.5µg/egg in ovo injection) and Zn (500µg/egg in ovo injection) groups respectively. On the seventeenth day of incubation, treatment solutions were administered into amniotic fluid of fertilized eggs. The results revealed that Se and Zn supplementation significantly (P < 0.05) enhanced hatchability, post-hatch growth, organ development, and liver antioxidant capability. Histopathological examination revealed a typical hepatocyte morphology, well-arranged cells, and a significant (P < 0.05) decrease in apoptosis in both selenium and zinc groups. Additionally, selenium and zinc produced auspicious effects on intestinal epithelium and villi surface area. Interestingly, our results revealed that IOF of Se and Zn modulated the expression of immune-related genes in comparison to the control and sham groups. Conclusively, IOF of Se and Zn augmented health and productivity by enhancing the cellular immunity in the broiler chickens, thus IOF can be utilized as an effective strategy to promote health and immunity in broiler chickens.

Iodine(III) reagents for the aromatic functionalization with inorganic groups

Iodine(III) reagents have gained importance in organic synthesis due to their strong oxidative properties in addition to several advantages over other related such as, non-toxic, green, easy to handle and in general safe for using. These characteristics become them useful tools and represent relevant alternatives to procedures which involves harsh and/or hazardous reaction conditions. They are versatile oxidants that has been largely used in the functionalization of a broad variety of aromatic nucleus, resulting in the introduction of several groups, including in the most general classification, organic and inorganics. In this sense, the metal-free arylation mediated by iodine(III) reagents is the most reported issue in the literature. Nevertheless, other relevant inorganic functionalities were also introduced. Herein, we review the most important procedures described to date for the aromatic functionalization with inorganic groups such as halogens, as well as the nitro-, azido, cyano-, sulfur- and selenium groups, under the iodine(III) chemistry.

Precision detection of cyanide, fluoride, and hydroxide ions using a new tetraseleno-BODIPY fluorescent sensor

A new chemosensor based on Seleno-BODIPY (4) was designed and synthesized for the rapid and sensitive detection of CN–, F−, and OH– ions in THF, exhibiting ultra-low detection limits of 26.26 nM, 43.05 nM, and 8.64 nM, respectively, through a turn-on fluorescent process. The seleno-funcionalization step was based on a novel methodology developed by our group, allowing direct functionalization of the BODIPY core. This procedure involves a quick reaction utilizing Ph2Se2 as a selenium source, BPO (benzoyl peroxide), and p-TSA (p-toluenesulfonic acid) in acetonitrile, enabling the production of the corresponding chalcogenated BODIPYs containing one to four selenium groups, demonstrating its versatility. The structure of BODIPY 4 was confirmed by HRMS, 1H, 13C, 77Se NMR, and IR spectra, and its photophysical properties were also evaluated. BODIPY 4 was applied to detect CN–, F−, and OH– ions in dual-mode detection (UV–Vis and fluorescence spectra), displaying a ratiometric response. The new probe exhibited a fast response time, visual color change from blue to fluorescent yellow, and high sensitivity and selectivity for these analytes over other selected anions. Mechanistic investigation through mass analysis revealed that the detection of these anions by BODIPY 4 occurs via an Aromatic Nucleophilic Substitution reaction with phenylselenide as the leaving group.

The effect of a selenium-based anti-inflammatory strategy on postoperative functional recovery in high-risk cardiac surgery patients - A nested sub-study of the sustain CSX trial

AimThe cardiac surgery-related ischemia-reperfusion-related oxidative stress triggers the release of cytotoxic reactive oxygen and nitrogen species, contributing to organ failure and ultimately influencing patients' short- and long-term outcomes. Selenium is an essential co-factor for various antioxidant enzymes, thereby contributing to the patients' endogenous antioxidant and anti-inflammatory defense mechanisms. Given these selenium's pleiotropic functions, we investigated the effect of a high-dose selenium-based anti-inflammatory perioperative strategy on functional recovery after cardiac surgery. Materials and methodsThis prospective study constituted a nested sub-study of the SUSTAIN CSX trial, a double-blinded, randomized, placebo-controlled multicenter trial to investigate the impact of high-dose selenium supplementation on high-risk cardiac surgery patients' postoperative recovery. Functional recovery was assessed by 6-min walk distance, Short Form-36 (SF-36) and Barthel Index questionnaires. Key findings174 patients were included in this sub-study. The mean age (SD) was 67.3 (8.9) years, and 78.7 % of the patients were male. The mean (SD) predicted 30-day mortality by the European System for Cardiac Operative Risk Evaluation II score was 12.6 % (9.4 %). There was no difference at hospital discharge and after three months in the 6-min walk distance between the selenium and placebo groups (131 m [IQR: not performed – 269] vs. 160 m [IQR: not performed – 252], p = 0.80 and 400 m [IQR: 299–461] vs. 375 m [IQR: 65–441], p = 0.48). The SF-36 and Barthel Index assessments also revealed no clinically meaningful differences between the selenium and placebo groups. SignificanceA perioperative anti-inflammatory strategy with high-dose selenium supplementation did not improve functional recovery in high-risk cardiac surgery patients.

Association of dietary selenium intake and all-cause mortality of Parkinson’s disease and its interaction with blood cadmium level: a retrospective cohort study

BackgroundParkinson’s disease (PD) is a slowly progressive neurodegenerating disease that may eventually lead to disabling condition and pose a threat to the health of aging populations. This study aimed to explore the association of two potential risk factors, selenium and cadmium, with the prognosis of Parkinson’s disease as well as their interaction effect.MethodsData were obtained from the National Health and Nutrition Examination Survey (NHANES) 2005–2006 to 2015–2016 and National Death Index (NDI). Participants were classified as Parkinson’s patients by self-reported anti-Parkinson medications usage. Cox regression models and restricted cubic spline models were applied to evaluate the association between PD mortality and selenium intake level as well as blood cadmium level. Subgroup analysis was also conducted to explore the interaction between them.ResultsA total of 184 individuals were included. In full adjusted cox regression model (adjusted for age, gender, race, hypertension, pesticide exposure, smoking status and caffeine intake), compared with participants with low selenium intake, those with normal selenium intake level were significantly associated with less risk of death (95%CI: 0.18–0.76, P = 0.005) while no significant association was found between low selenium intake group and high selenium group (95%CI: 0.16–1.20, P = 0.112). Restricted cubic spline model indicated a nonlinear relationship between selenium intake and PD mortality (P for nonlinearity = 0.050). The association between PD mortality and blood cadmium level was not significant (95%CI: 0.19–5.57, P = 0.112). However, the interaction term of selenium intake and blood cadmium showed significance in the cox model (P for interaction = 0.048). Subgroup analysis showed that the significant protective effect of selenium intake existed in populations with high blood cadmium but not in populations with low blood cadmium.ConclusionModerate increase of selenium intake had a protective effect on PD mortality especially in high blood cadmium populations.

Selenium supplementation in inactive moderate to severe Graves’ orbitopathy patients: a randomized controlled trial

ABSTRACT Purpose This study was designed to evaluate the effect of selenium supplementation in inactive moderate-severe Graves’ orbitopathy (GO) patients. Methods This study was a single-center, placebo-controlled, double-masked, randomized trial. Inactive moderate-severe GO participants were randomized to receive six months of 200 micrograms/day of selenium supplementation or placebo. Thorough eye exams, clinical activity score (CAS), Graves’ Ophthalmopathy quality of life questionnaire (GO-QOL), and serum selenium level were evaluated at baseline and 6 months after the interventions. The chi-squared or Fisher’s exact test was used to compare categorical variables. The t-test and the paired t-test were used to compare continuous variables between two independent samples and two dependent samples, respectively. Results A total of 25 participants were enrolled, 13 in the selenium group and 12 in the placebo group. Both groups had adequate baseline serum selenium levels at 98.96 ± 15.63 mcg/L and 102.55 ± 17.71 mcg/L, respectively. After 6 months of intervention, the selenium group showed a greater improvement in palpebral aperture (mean difference: −1.4 ± 1.7 mm, p = .04) compared to the placebo group (−0.3 ± 2.7 mm). Notably, 5(41.67%) people in the placebo group developed larger palpebral apertures. Proptosis, ocular motility, and soft tissue signs did not change significantly. GO-QOL and CAS score improvement showed no statistically significant difference between both groups. Minor adverse effects were observed. Conclusions Selenium supplementation has a positive effect on eyelid aperture even in inactive moderate-to-severe GO patients with a sufficient baseline selenium level.

Selenium supplementation and placebo are equally effective in improving quality of life in patients with hypothyroidism.

We investigated whether selenium supplementation improves quality-of-life (QoL) in patients with autoimmune thyroiditis (ID:NCT02013479). We included 412 patients ≥18 years with serum thyroid peroxidase antibody (TPOAb) level ≥100 IU/mL in a multicentre double-blinded randomised clinical trial. The patients were allocated 1:1 to daily supplementation with either 200 μg selenium as selenium-enriched yeast or matching placebo tablets for 12 months, as add-on to levothyroxine (LT4) treatment. QoL, assessed by the Thyroid-related Patient-Reported-Outcome questionnaire (ThyPRO-39), was measured at baseline, after six weeks, three, six, 12, and 18 months. In total, 332 patients (81%) completed the intervention period, of whom 82% were women. Although QoL improved during the trial, no difference in any of the ThyPRO-39 scales was found between the selenium group and the placebo group after 12 months of intervention. In addition, employing linear mixed model regression no difference between the two groups was observed in the ThyPRO-39 composite score (28.8 [95%CI:24.5-33.6] and 28.0 [24.5-33.1], respectively; P=0.602). Stratifying the patients according to duration of the disease at inclusion, ThyPRO-39 composite score, TPOAb level, or selenium status at baseline did not significantly change the results. TPOAb levels after 12 months of intervention were lower in the selenium group than in the placebo group (1995 [95%CI:1512-2512] vs. 2344 kIU/L [1862-2951]; P=0.016) but did not influence LT4 dosage or free triiodothyronine/free thyroxin ratio. In hypothyroid patients on LT4 therapy due to autoimmune thyroiditis, daily supplementation with 200 μg selenium or placebo for 12 months improved QoL to the same extent.

Palliative Effect of Combined Application of Zinc and Selenium on Reproductive Injury Induced by Tripterygium Glycosides in Male Rats.

The long-term use of tripterygium glycosides (TG) can lead to male reproductive damage. Research indicates that zinc and selenium exhibit a synergistic effect in the male reproductive system, with the combined preparation demonstrating superior therapeutic effects compared to individual preparations. The purpose of this study was to explore the specific mechanism by which zinc and selenium mitigate reproductive toxicity induced by TG in male rats. Rats were randomly assigned to three groups: control group (C group), model group (M group, receiving TG at 30 mg/kg/day), and model + zinc + selenium group (ZS group). The ZS group was also given TG gavage for the first 4 weeks. Starting from the fifth week until the conclusion of the eighth week, the ZS group received an additional protective treatment of 10 mg/kg/day Zn and 0.1 mg/kg/day Se 4 h after TG administration. Following euthanasia, blood samples, rat testis, and epididymis tissues were collected for further experiments. Combined zinc-selenium treatment corrects the imbalance of zinc-selenium homeostasis in testicular tissue induced by TG. This is achieved by upregulating the expression of metal transcription factor (MTF1) and zinc transporters ZIP8 and ZIP14 and downregulating the expression of ZnT10. Improvement of zinc and selenium homeostasis enhanced the expression of zinc-containing enzymes (ADH, LDH, and ALP) and selenoproteins (GPx1 and SELENOP) in the testis. At the same time, zinc and selenium mitigate TG-induced reproductive damage by promoting the activity of antioxidant enzymes and upregulating the expression of proteins associated with the oxidative stress pathway, including Nrf2, Keap1, HO-1, PI3K, and p-AKT.

Transition metal-free C(sp3)-H selenation of β-ketosulfones.

The installation of selenium groups has become an essential step across a number of industries such as agrochemicals, drug discovery, and materials. However, direct C(sp3)-H selenation, which is most atom economical, remains a formidable challenge, and only a few examples have been reported to date. In this article, we introduce the transition metal-free C(sp3)-H selenation with the easily available β-ketosulfones and diselenides as the material source. This benign protocol permits access to a broad spectrum of α-aryl(alkyl) seleno-β-ketosulfones in high yields with outstanding functional group compatibility. Distinct advantages of this protocol over all previous methods encompass the utilization of base and air as an oxidant, room temperature, and enhanced green chemistry matrices.

Impact of Selenium Deficiency on Clinical Outcomes in Newly Diagnosed Heart Failure Patients in Japan.

Previous studies conducted have reported higher mortality and heart failure readmission rates in heart failure patients with selenium deficiency. However, these studies included patients with advanced heart failure, which may have confounded the relationship between selenium deficiency and heart failure pathology. This study aimed to explore the clinical characteristics and outcomes of heart failure patients with selenium deficiency who were newly diagnosed and hospitalized for heart failure in Japan. A total of 256 patients, who were admitted to our hospital for the first time due to heart failure, were included in this study. The patients were divided into two groups: a low selenium group (LS group, n=132) and a normal selenium group (NS group, n=124). Clinical features and outcomes were compared between the two groups, including 1-y mortality and readmissions due to heart failure. Among the patients admitted with heart failure, 51.6% exhibited selenium deficiency. The LS group showed a higher proportion of females (65.4% vs. 46.4%, p=0.003) and lower albumin levels (3.2±0.5 g/dL vs. 3.5±0.5 g/dL, p<0.001) compared to the NS group. The LS group had a significantly higher readmission rate for heart failure (31.8% vs. 17.7%, p=0.009). Multivariate analysis revealed heart failure patients with low selenium as an independent factor for readmission due to heart failure. Newly diagnosed heart failure patients with low selenium demonstrated a high readmission rate for heart failure.

Safety and Efficacy of Selenium on Recovery of Hospitalized Patients with COVID-19: A Randomized Controlled Clinical Trial

Background: Various micronutrients have been used to manage patients affected by coronavirus disease 2019 (COVID-19). However, data on the potential benefits of selenium for COVID-19 patients are scarce. Objectives: This study was conducted to monitor the efficacy and safety of selenium supplementation in COVID-19 patients hospitalized at Shahid Mostafa Khomeini Hospital in Ilam, Iran, in 2021. Methods: In this randomized controlled trial, 100 COVID-19 cases were included and divided into two groups: The selenium group (n = 50) was prescribed the hospital treatment protocol as well as selenium supplementation in a daily dose of 200 µg, and the control group (n = 50) that received only the hospital treatment protocol. Laboratory tests, including platelet, white blood count (WBC), hemoglobin, ferritin, c-reactive protein (CRP), and erythrocyte sedimentation rate (ESR), were performed before the trial and on the 14th day. Two groups were compared based on laboratory findings, duration of hospitalization, and dependency on mechanical ventilation. Results: In the selenium group, platelets, WBC, and hemoglobin rose remarkably compared to their pre-treatment concentrations (P &lt; 0.05), while a considerable drop was detected in levels of ESR, CRP, and ferritin (P &lt; 0.05). The mean length of stay in the selenium and control groups was 9.27 ± 13.50 and 11.45 ± 14.33 days, respectively (P = 0.401). The mean mechanical ventilation dependency days in the selenium and control groups were 9.65 ± 11.71 and 7.45 ± 4.93, respectively, implying no statistically significant difference (P = 0.307). Conclusions: Selenium supplement may reduce levels of inflammatory markers in COVID-19 patients. Nevertheless, further trials are required to monitor its clinical effectiveness.

Perioperative selenium administration in cardiac surgery patients, a way out to reduce post surgical adversities? A meta analysis.

The oxidative damage suffered in cardiac surgery is associated with declining trace elements which lead to the development of multi organ dysfunction (MOD), acute kidney injury (AKI), or increased length of hospital stay (LOS). Recent evidence shows the cardioprotective role of the trace element selenium as it mitigates worsening outcomes post cardiac surgery. Hence, this meta analysis aims to investigate the role of selenium in lowering cardiac surgery related adverse outcomes. Literature search of five electronic databases was performed from the inception of the paper till 29th July, 2023. Eligibility criteria included; (a) randomized clinical trials with Adult patients (≥18 years) undergoing cardiac surgery (b) intervention with selenium pre or/and postoperatively; (c) a control group of a placebo, normal saline, or no selenium. Outcomes of interest include postoperative mortality, LOS in the hospital and Intensive Care Unit (ICU), AKI, troponin I, and Creatinine Kinase-MB (CK-MB). The Cochrane bias assessment tool was used to evaluate the risk of bias. Outcomes were pooled with the Mantel-Haenszel Random-effects model using Review Manager. Seven RCTs with 2,521 patients and 65% of males were included in this paper. No noticable differences were observed between selenium and control groups in terms of postoperative AKI, mortality, LOS in hospital and ICU, troponin I, and CK-MB levels. All studies had a low risk of bias on quality assessment. Our meta analysis demonstrated no discernible effects of selenium infusion on post operative complications among patients undergoing cardiac surgery. Further large scale multi centered studies comparing the protective role of selenium with combined therapy of other bioactive agents are needed to provide convincing explanations. PROSPERO Identifier: 424920.

Effects of Selenium Supplementation on the Indices of Disease Activity, Inflammation and Oxidative Stress in Patients with Rheumatoid Arthritis: a Randomized Clinical Trial.

The aim of study was to evaluate the effect of selenium supplementation on disease activity, inflammation, and oxidative stress in patients with rheumatoid arthritis (RA).This study was a randomized double-blind placebo-controlled trial on 59 patients with RA. Participants were randomly divided to receive 200μg/day of selenium or a placebo for 12weeks. The disease activity score (DAS.CRP and DAS.ESR), erythrocyte sedimentation rate (ESR), serum levels of C-reactive protein (CRP), fasting blood glucose, lipids, antibodies to cyclic citrullinated protein (anti-CCP), nitric oxide, glutathione, and total antioxidant capacity were assessed. The mean of DAS.CRP and DAS.ESR decreased significantly within both study groups after the intervention. However, the between-group comparisons revealed no significant differences. The CRP levels decreased significantly in the selenium group, and this decrease was near the significance level compared to the placebo (P = 0.05). However, after adjusting for baseline values, the observed difference between groups did not remain significant. In addition, the values of ESR and anti-CCP decreased significantly within the selenium group. Although, between-group comparison did not statistically significant, the change in ESR and anti-CCP in the selenium group was small clinically relevant compared to the placebo [the effect size (95% CI) for ESR: 0.38 (- 0.14, 0.89), and for anti-CCP: 0.32 (- 0.2, 0.83)]. Our study showed that selenium caused a small clinically relevant improvement in some RA biomarkers such as ESR and anti-CCP. Future studies that evaluate the effects of novel forms of supplements such as selenium nanoparticles on the clinical symptoms and biomarkers of RA are suggested.Trial Registration: At www.irct.ir as IRCT20190924044869N1 on 2020-06-14.

The Effects of Selenium Supplementation in the Treatment of Autoimmune Thyroiditis: An Overview of Systematic Reviews.

The available evidence on selenium supplementation in the treatment of autoimmune thyroiditis (AIT) was inconclusive. This research serves to assess the effects of selenium supplementation in the treatment of AIT. Online databases including PubMed, Web of Science, Embase, and the Cochrane Library were searched from inception to 10 June 2022. The AMSTAR-2 tool was used to assess the methodological quality of included studies. The information on the randomized controlled trials of the included studies was extracted and synthesized. The GRADE system was used to assess the certainty of evidence. A total of 6 systematic reviews with 75 RCTs were included. Only one study was rated as high quality. The meta-analysis showed that in the levothyroxine (LT4)-treated population, thyroid peroxidase antibody (TPO-Ab) levels decreased significantly in the selenium group at 3 months (SMD = -0.53, 95% CI: [-0.89, -0.17], p < 0.05, very low certainty) and 6 months (SMD = -1.95, 95% CI: [-3.17, -0.74], p < 0.05, very low certainty) and that thyroglobulin antibody (Tg-Ab) levels were not decreased. In the non-LT4-treated population, TPO-Ab levels decreased significantly in the selenium group at 3 and 6 months and did not decrease at 12 months. Tg-Ab levels decreased significantly in the selenium group at 3 and 6 months and did not decrease at 12 months. The adverse effects reported in the selenium group were not significantly different from those in the control group, and the certainty of evidence was low. Although selenium supplementation might reduce TPO-Ab levels at 3 and 6 months and Tg-Ab levels at 3 and 6 months in the non-LT4-treated population, this was based on a low certainty of evidence.

Effects of vitamin E and selenium yeast on cognitive performance of pups whose dams were subjected to prenatal noise stress

This study investigated the effects of vitamin E and selenium yeast on the cognitive performance of pups whose dams were subjected to prenatal noise stress (PNS). Twenty-five pregnant Wistar rats were divided into five groups, group 1 (negative control; received 1 mL/kg of distilled water without noise stress (NS); group 2: (positive control), received 1 mL/kg of distilled water group 3: received vitamin E; 100 mg/kg/day group 4: selenium yeast (0.4 mg/kg/day) and group 5: vitamin E (100 mg/kg/day bw) and selenium yeast (0.4 mg/kg/day). All administrations were done 30 min before the induction of white noise at 100 dB/4 h (0900–1300 h) /day for 15 days. On gestational day 21, five pups (n = 5) were randomly selected from each group. The pups were subjected to cognitive tests using the Y-maze apparatus on days 21 and 22. All experimental animals were sacrificed on day 23 for tissue processing. Data were analyzed using one-way ANOVA and a value of p˂0.05 was considered statistically significant. The serum corticosterone (CORT) levels statistically increased in group 2 (p˂0.001) compared with groups 1, 3, 4 and 5. Brain homogenate showed an increased level of Malondialdehyde (MDA), decreased levels of glutathione reeducates (Gpx), catalase (CAT) and superoxide dismutase (SOD) in group 2 compared to 1. Glial cell activation was prominient in group 2 compared to group 1. Prenatal noise stress-induced cognitive impairments in pups whose dams were exposed to NS, but this impairment was mitigated with the administration of vitamin E, selenium yeast and combined administration of selenium yeast and vitamin E.

Investigation of the effect of oral selenium on the reduction of clinical symptoms and joint pain in patients with rheumatoid arthritis in the Iranian population.

Rheumatoid arthritis (RA) is a common inflammatory joint disease. Since inflammation and nitrosative stress play an important role in the pathogenesis of RA, drugs that have antioxidant and anti-inflammatory effects can be effective as adjuvant treatment in these patients. Selenium is a compound that has been shown in recent studies to have anti-inflammatory and antioxidant effects. Therefore, the aim of this study was to investigate the effect of oral selenium on the reduction of clinical symptoms and joint pain in patients with RA. Fifty one patients with moderate and severe RA were randomly divided into selenium and placebo groups. The first group of patients received century Selenium drug at a dose of 200 micrograms twice a day for 12 weeks along with standard RA interventions and treatments, and the second group received standard treatments of RA along with a placebo. Clinical symptoms were evaluated with standard indicators to evaluate disease activity before and after the intervention in the 12th week. Examination of clinical symptoms at the end of the study showed that in the selenium group and after 12 weeks, a reduction in clinical symptoms and joint pain were observed, which was statistically significant compared to before the study began. Meanwhile, no significant changes were observed in the patients of the placebo group in terms of reducing symptoms and joint pains. A dose of 200 micrograms of oral selenium twice a day for 12 weeks can significantly reduce clinical symptoms and joint pain in patients with RA. This article is protected by copyright. All rights reserved.

Selenium and Omega-3 Fatty Acids Ameliorate Highly Active Anti-Retroviral Therapy (HAART)-induced Reproductive Impairment in Male Wistar Rats.

Highly active anti-retroviral therapy (HAART) is currently the main stay in the treatment of Human Immunodeficiency Virus (HIV) disease. This treatment regimen typically combines three or more antiretroviral drugs and like most drug combinations or polypharmacy, has side effects including those on reproductive function which could place HIV patients on HAART under double risk in terms of reproductive function. Part of tissue damage following HAART administration is blamed on oxidative stress. We therefore sought to explore effects of Omega 3 and Selenium, two common antioxidants on HAART-induced male reproductive impairment in a non-HIV animal model. Sixteen male adult Wistar rats weighing 120g to 250g used for the study were grouped into 4 groups of four rats each (control, HAART-only, HAART + Omega 3 and HAART + Selenium groups). Duration of daily administration was six weeks. Results showed no significant changes in pH of epidydimal semen among the groups. Sperm count and viability were significantly reduced in HAART-only compared with control (p<0.05) but increased in HAART + Omega 3 and HAART + Selenium groups compared with HAART-only group (p< 0.05). Sperm motility was significantly reduced in HAART-only compared with control group (p< 0.05). A significantly higher percentage of total sperm defects was observed in HAART-only group compared with control (p <0.05) but significantly lower in the HAART + Selenium compared with HAART-only groups (p<0.05). Serum testosterone was significantly reduced in HAART-only compared with control groups (p<0.05) but significantly increased in HAART + Omega 3 and HAART + Selenium groups compared with HAART- only group (p<0.05). Serum concentration of luteinizing and follicle stimulating hormones were not significantly different among the groups. Testicular concentration of malondialdehyde was significantly increased in HAART-only compared with control (p<0.05) but significantly reduced in HAART + Omega 3 and HAART + Selenium groups compared with HAART-only group (p<0.05 in each). Testicular glutathione peroxidase activity was significantly reduced in HAART-only and HAART + Selenium groups compared with control (p< 0.05), but significantly higher in HAART + Omega 3 and HAART + Selenium compared with HAART-only groups (p<0.05 each). Testicular superoxide dismutase activity was significantly lower in the HAART-only and HAART + Selenium compared with control (p<0.05) but significantly higher in HAART + Omega 3 and HAART + Selenium compared with HAART-only groups (p<0.05 each). Level of tumour necrosis factor - alpha in testes was significantly higher in HAART-only (p<0.05) but lower in the HAART + Selenium (p<0.05) groups compared with control. Tumor necrosis factor-alpha was however significantly reduced in HAART + Omega 3 and HAART + Selenium groups compared with HAART-only (p<0.05 each) groups. Interleukin-6 levels were significantly increased in all HAART-administered groups compared with control (p<0.05 each) though significantly reduced in HAART + Omega 3 and HAART + Selenium compared with HAART-only groups (p<0.05 each). In conclusion, co-administration of Omega 3 or Selenium with HAART ameliorates HAART-induced male reproductive impairment, alteration in redox and inflammatory status in rats. Keywords: HAART, male reproductive impairment, Omega 3, Selenium.

The influence of interventional measures on metabolic factors in fluoride and aluminum combined poisoning bones

ABSTRACT This study aimed to evaluate the effects of soybean, selenium and spirulina on bone metabolic factors in rats with combined fluoride and aluminum poisoning.Methods:Sixty SD rats were allocated to five groups: A control group, a high-fluoride aluminum group, a high-fluoride aluminum plus soybean group, a high-fluoride aluminum plus selenium group, and a high-fluoride aluminum plus spirulina group. Serum samples were collected and radioimmunoassay (RIA) was used to measure osteocalcin (BGP), calcitonin (CT), parathyroid hormone (PHT) and insulin growth factor I (IGF-1) levels after 90 and 165 days of intervention. 1. When comparing the serum BGP level in the high-fluorine aluminum plus selenium group with the high-fluorine aluminum group, suggesting that the addition of selenium intervention was beneficial in reducing the effect of high-fluorine aluminum on bone homeostasis. 2. After 90 days and 165 days, the difference in serum CT levels between the intervention group and the control group was not statistically significant, suggesting an effect of the intervention factors.3. After 90 days of exposure, the three intervention groups had lower serum PTH levels (p < 0.00), inferring the efficacy of the interventions.4. After 90 days, serum IGF-1 levels were elevated in the Spirulina group compared with the high-fluorinated aluminum group, and the difference was statistically significant, suggesting that the addition of Spirulina intervention may counteract the inhibition of bone growth by high-fluorinated aluminum. The intervention of soybean, selenium, and spirulina can counterbalance the effects of fluoride and aluminum on bone metabolism and slow down the process of bone turnover.